Zura Bio Ltd

Zura Bio Ltd (Nasdaq: ZURA) is a clinical-stage biopharmaceutical company focused on developing therapies for immunological and inflammatory diseases, with its pipeline targeting conditions including alopecia areata and prurigo nodularis. The company became a publicly traded entity through a SPAC merger and filed its quarterly report on Form 10-Q with the SEC on August 12, 2022, under accession number 0001410578-22-002385, reflecting its status as an active reporting company in the biotechnology and life sciences sector. Zura Bio operates in a competitive immunology landscape alongside established and emerging biotech peers. For full filing history, pipeline milestones, and SPAC-deal analytics on ZURA, sign up for complete data access at SpacDesk.